natgillin/translations-raw huggingface dataset:
In very rare cases, anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur. 
U vrlo rijetkim slučajevima mogu se javiti reakcije anafilaktičkog tipa (alergijski edem, urtikarije, eritema, kolaps, dispnea, blijede mukozne sluznice).
In case treatment for a longer period than 5 days is regarded as necessary, careful monitoring of potential adverse events should be implemented. 
U slučaju liječenja u razdoblju dužem od 5 dana potrebno je pažljivo praćenje mogućih nuspojava.
29 route des Industries 37530 Pocé-sur-Cisse FRANCE 
37530 Pocé-sur-Cisse
Vomiting can be associated with serious, severely debilitating conditions and the cause should be investigated. 
Povraćanje može biti povezano s teškim i ozbiljnim stanjima, te zbog toga uzroci moraju biti istraženi.
Do not use this veterinary medicinal product after the expiry date which is stated on the label of the vial after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi poslije EXP.
CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant. 
CYP2D15 i CYP3A12 su identificirani kao pseći izoformi uključeni u jetrenu biotransformaciju maropitanta.
The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats). 
Antiemetička djelotvornost maropitanta protiv centralnih i perifernih emetika dokazana je u eksperimentalnim ispitivanjima uključujući amorfin, cispaltin i sirup ipekaka (pas) i ksilazin (mačka).
Cerenia tablets are available in 16 mg, 24 mg, 60 mg and 160 mg strength. 
Cerenia tablete su dostupne u jakosti od 16 mg, 24 mg, 60 mg i 160 mg.
• For the treatment of vomiting, in combination with other supportive measures. 
• Za liječenje povraćanja, u kombinaciji s drugim potpornim mjerama.
To remove a tablet from the blister the following sequence should be carried out; 
Da bi se tableta izvadila iz blistera pratite slijedeće korake:
Maropitant displays non-linear pharmacokinetics (AUC increases more than proportionally with increasing dose) when administered orally within the 1-16 mg/kg dose range. 
Maropitant pokazuje nelinearnu farmakokinetiku (povećanje AUC je više nego proporcionalno s povećanjem doze) kada se daje peroralno unutar granica doze od 1-16 mg/kg.
By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting. 
Inhibicijom vezanja P tvari u centru za povraćanje, maropitant postaje djelotvoran protiv nervnih i humoralnih (centralnih i perifernih) uzroka povraćanja.
• For the prevention and treatment of vomiting, in conjunction with Cerenia solution for injection and in combination with other supportive measures. 
• Za sprječavanje i liječenje povraćanja uz potpornu terapiju Cerenia otopinom za injekcije i u kombinaciji s drugim potpornim mjerama.
Cerenia is not a sedative and some motion sick dogs may show nausea-like signs during travel such as salivation and lethargy. 
Cerenia nije sedativ i neki psi koji pate od bolesti putovanja mogu pokazati znakove slične mučnini kao na primjer pojačano slinjenje i letargiju.
Manufacturer responsible for batch release: FAREVA AMBOISE Zone Industrielle, 
Proizvođač odgovoran za puštanje serije u promet: FAREVA AMBOISE
Maropitant is non-sedative and should not be used as a sedative in motion sickness. 
Maropitant nema sedirajući učinak i ne treba ga koristiti kao sedativ za bolest putovanja.
Prevention of motion sickness 
Sprječavanje bolesti putovanja
During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration. 
Tijekom kliničkih ispitivanja razine maropitanta u plazmi odgovaraju učinkovitosti od 1 sat nakon davanja.
Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed. 
Povraćanje može biti povezano s teškim i ozbiljnim stanjima koja oslabljuju organizam uključujući probavne zastoje (smetnje), zbog toga treba provesti ciljane dijagnostičke pretrage.
Plasma protein binding of maropitant in cats was estimated to be 99.1%. 
Vezanje proteina plazme za maropitant kod mačaka je procijenjeno na 99,1%.
Shelf life after first opening the vial: 28 days. 
Rok valjanosti poslije prvog otvaranja spremnika: 28 dana.
An unused half tablet should be returned to the opened blister and kept within the cardboard outer. 
Neiskorištenu polovinu tablete treba vratiti u već otvoreni blister, te vratiti u kartonsku kutiju.
Cerenia tablets were well tolerated when administered for 15 days at dosages up to 10 mg/kg bodyweight per day. 
Cerenia tablete se dobro podnose kada su davane 15 dana u dozi do 10 mg/kg tjelesne mase dnevno.
Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml. 
Nakon jedne intravenozne doze od 1 mg/kg početna koncentracije u plazmi bila je 363 ng/ml.
Cerenia tablets have been shown to be effective in the treatment of emesis, however where the frequency of vomiting is high, orally administered Cerenia may not be absorbed before the next vomiting event occurs. 
Cerenia tablete su se pokazale kao uspješna terapija protiv povraćanja, iako se kod slučajeva učestalog povraćanja peroralno aplicirana Cerenia možda neće apsorbirati prije slijedećeg akta povraćanja.
Each tablet contains 0.075% w/w Sunset Yellow (E110) as a colorant. 
Pomoćne tvari: Svaka tableta sadržava 0,075% w/w Sunset žutu (E110) kao bojilo.
Incidents of pre-travel vomiting, usually within two hours post-dosing were commonly reported after administration of the 8 mg/kg dose. 
Često su prijavljeni slučajevi povraćanja prije putovanja, obično unutar 2 sata nakon davanja doze od 8 mg/kg.
Treatment may be repeated for a maximum of two consecutive days. 
Lijek se može dati ponovo maksimalno dva uzastopna dana.
In vivo studies in dogs demonstrated the anti-emetic efficacy of maropitant against central and peripheral emetics including apomorphine, cisplatin and syrup of ipecac. 
In vivo ispitivanja na psima pokazuju antiemetičku djelotvornost maropitanta protiv centralnih i perifenih emetika uključujući amorfin, cispaltin i sirup ipekaka.
CYP1A and CYP3A-related enzymes were identified as the feline isoforms involved in the hepatic biotransformation of maropitant. 
CYP1A i CYP3A-vezani enzimi su identificirani kao mačji izoformi uključeni u jetrenu biotransformaciju maropitanta.
In laboratory studies, maropitant has been shown to be a potential eye irritant. 
Laboratorijska ispitivanja su pokazala da maropitant može nadražiti oči.
The volume of distribution at steady-state (Vss) determined after intravenous administration at 1-2 mg/kg ranged from approximately 4.4 to 7.0 l/kg. 
Volumen distribucije u stanju mirovanja (Vss) određen nakon i.v. aplikacije 1-2 mg/kg bio je u granicama od otprilike 4,4 do 7,0 l/kg.
To prevent vomiting, tablets should be given more than 1 hour in advance. 
Da bi se spriječilo povraćanje, potrebno je tabletu dati barem jedan sat unaprijed.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
13. RIJEČI “SAMO ZA PRIMJENU NA ŽIVOTINJAMA ” I UVETI ILI OGRANIČENJA U POGLEDU OPSKRBE I PRIMJENE, ako je primjenjivo
In cats, moderate to severe response to injection is very commonly observed (in approximately one third of cats). 
Kod mačaka se vrlo često (otprilike kod jedne trećine) javlja umjerena do ozbiljna reakcija.
Cerenia should be used with caution in animals suffering from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and K-ion channels. 
Cereniju treba koristiti s oprezom kod jedinki koje imaju srčane poremećaje ili onih koje imaju predispoziciju srčane insuficijencije zato što maropitant ima sklonost prema kanalima iona kalcija i kalija.
The use of Cerenia solution for injection against vomiting due to motion sickness is not recommended. 
Korištenje Cerenia otopine za injekcije nije preporučeno za sprječavanje povraćanja uzrokovanog bolešću putovanja.
As maropitant is accumulated in the body during a 14-day treatment period due to metabolic saturation, careful monitoring of liver function should be implemented during long term treatment. 
Pošto je maropitant akumuliran u tijelu tijekom perioda liječenja u trajanju od 14 dana uslijed zasićenja metabolizma, tijekom dugotrajnog perioda liječenja treba provesti pažljivo praćenje funkcije jetre vezane za bilo koju nuspojavu.
Signs of nausea including excessive salivation and lethargy might remain during treatment. 
Simptomi mučnine uključujući pojačano slinjenje i letargičnost mogu se pojaviti za vrijeme liječenja.
• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness. 
• Za sprječavanje povraćanja i smanjenje mučnine, osim one uzrokovane bolešću putovanja.
Due to the frequent occurrence of transient pain during subcutaneous injection, appropriate animal restraining measures may have to be applied. 
Zbog učestalog pojavljivanja prolazne boli prilikom subkutane aplikacije potrebno je propisno sputati životinju.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Tablets 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija / Tableta
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight). 
Cerenia otopina za injekciju daje se supkutano ili intravenozno, jednom dnevno u dozi od 1 mg/kg tjelesne težine (1 ml/10 kg tjelesne težine).
The bioavailability of maropitant after subcutaneous administration in cats was 91.3%. 
Procjene bioraspoloživosti maropitanta nakon subkutane primjene kod mačaka je bila 91,3%.
Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration). 
Osim prolaznih reakcija na mjestu uboda nakon subkutane primjene, proizvod Cerenia otopina za injekciju dobro su podnijeli psi i mlade mačke dnevno injicirani s do 5 mg kg (5 puta veća doza od preporučene) kroz 15 uzastopnih dana (3 puta duže preporučeno trajanje primjene).
The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel. 
Antiemtički učinak traje najmanje 12 sati, što omogućuje davanje lijeka večer prije putovanja.
The tablets also contain Sunset Yellow (E110) as a colorant. 
Tablete sadrže i Sunset žutu (E110) kao bojilo.
PACKAGE LEAFLET: Cerenia tablets for dogs 
UPUTA O VMP: Cerenia tablete za pse
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Solution for injection 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU Kartonska kutija / Otopina za injekciju
Tablets are breakable along the score line on the tablet. 
Tablete se mogu prepoloviti po razdjelnoj liniji.
Products such as Cerenia should be used in conjunction with other supportive measures such as dietary control and fluid replacement therapy, as recommended by your veterinary surgeon. 
Proizvodi poput Cerenie se trebaju koristiti u kombinaciji s drugim potpornim mjerama poput dijetne prehrane i nadoknade izgubljene tekućine, a u skladu i prema preporuci odgovornog veterinara.
The effect duration is approximately 24 h and therefore treatment can be given the night before administration of an agent that may cause emesis e.g. chemotherapy. 
Djelotvornost traje otprilike 24 sata te se stoga terapija može dati večer prije davanja tvari koja uzrokuje povraćanje npr. kemoterapija.
D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
OSTALI UVJETI I ZAHTJEVI ODOBRENJA ZA STAVLJANJE U PROMET>
• For the treatment and prevention of nausea induced by chemotherapy. 
• Za liječenje i sprječavanje mučnine izazvane kemoterapijom.
Cerenia 16 mg tablets for dogs Cerenia 24 mg tablets for dogs Cerenia 60 mg tablets for dogs Cerenia 160 mg tablets for dogs 
Cerenia 16 mg tablete za pse Cerenia 24 mg tablete za pse Cerenia 60 mg tablete za pse Cerenia 160 mg tablete za pse
Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels. 
Cerenia se ne smije davati istodobno s antagonistima kalcijevih kanala jer maropitant ima sklonost prema njima.
Cerenia 16 mg tablets for dogs Cerenia 24 mg tablets for dogs Cerenia 60 mg tablets for dogs Cerenia 160 mg tablets for dogs maropitant 
Cerenia 16 mg tablete za pse Cerenia 24 mg tablete za pse Cerenia 60 mg tablete za pse Cerenia 160 mg tablete za pse maropitant
The efficacy of Cerenia in reduction of nausea was demonstrated in studies using a model (xylazineinduced nausea). 
Učinkovitost Cerenie za smanjivanje mučnine dokazana je ispitivanjima korištenjem modela (mučnina izazvana ksilazinom).
The tablets have a score line allowing the tablet to be halved, with the letters “MPT” and figures denoting the quantity of maropitant on one side, the reverse side is blank. 
Slova „MPT“ i broj koji se odnosi na količinu maropitanta otisnuti su s jedne strane, dok je obrnuta strana prazna.
In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. 
U slučaju nehotičnog samo injiciranja, odmah potražiti pomoć liječnika i pokažite mu oputu o VMP ili etiketu.
It is recommended to initiate treatment of emesis with Cerenia solution for injection. 
Preporučuje se započeti liječenje povraćanja s Cerenia otopinom za injekcije.
Cerenia should be used with caution in animals suffering from or with predisposition for heart diseases. 
Cereniju treba koristiti s oprezom kod jedinki koje imaju srčane poremećaje ili onih koje imaju predispoziciju srčane insuficijencije.
Each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate. 
Svaka tableta sadržava 16 mg, 24 mg, 60 mg ili 160 mg maropitanta u obliku maropitant citrat monohidrata.
The efficacy of Cerenia in reduction of nausea in cats was demonstrated in studies using a model (xylazine-induced nausea). 
Učinkovitost Cerenie za smanjivanje mučnine dokazana je ispitivanjima korištenjem modela (mučnina izazvana xylazinom).
Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS. 
Maropitant je jak i selektivan antagonist receptora neurokinin (NK-1), koji djeluje inhibirajući na vezanje P tvari, neuropeptida iz porodice tahikinina, u CNS-u.
To prevent vomiting induced by motion sickness, Cerenia tablets should be administered once daily, at a dose of 8 mg maropitant per kg bodyweight, using the numbers of tablets given in the table below. 
Za sprječavanje povraćanja uzrokovanog bolešću putovanja, Cerenia tablete treba dati jednom dnevno, u dozi od 8 mg maropitanta na kilogram tjelesne težine, koristeći broj tableta naveden u ispod priloženoj tabeli.
Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range. 
Maropitant pokazuje linearnu kinetiku kada se daje subkutano unutar granica doze od 0,25-3 mg/kg.
Cerenia 10 mg/ml solution for injection for dogs and cats is available in 20 ml amber glass vials. 
Cerenia 10 mg/ml otopina za injekciju za pse i mačke pakirana je u smeđoj staklenoj bočici od 20 ml.
Cerenia tablets are supplied in blister packs with four tablets per pack. 
15. OSTALE INFORMACIJE Cerenia tablete pakirane su po četiri komada u blisteru.
Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting. 
Dobra veterinarska praksa preporučuje da se antiemetici koriste uz potporu drugih mjera kao što su dijetna prehrana i nadoknada izgubljenih tekućina dok se terapira osnovni uzrok povraćanja.
Amber molded glass type 1 vial, 20 ml, chlorobutyl rubber stopper and aluminium overseal with flip-off button. 
Bočica od smeđeg stakla (tip I), od 20 ml, zatvorena klorbutilnim čepom i aluminijskom kapicom i plastičnim poklopcem.
In dogs, Cerenia solution for injection can be used to treat or prevent vomiting once daily for up to 5 days. 
Kod pasa Cerenia otopina za injekciju može se davati za liječenje ili sprječavanje povraćanja u, jednom dnevno do maksimalno pet uzastopnih dana.
The bioavailability of maropitant after subcutaneous administration in dogs was 90.7%. 
Procjene bioraspoloživosti maropitanta kod pasa nakon subkutane primjene je bila 90,7.
Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family. 
Maropitant je antagonist receptora neurokinin 1 (NK1), djeluje inhibirajući na vezanje P tvari, neuropeptida iz porodice tahikinina, u CNS-u.
Cerenia Solution for Injection: FAREVA AMBOISE Zone Industrielle, 29 route des Industries 37530 Pocé-sur-Cisse FRANCE 
Cerenia otopina za injekciju: FAREVA AMBOISE Zone Industrielle, 29 route des Industries
ATCvet code: QA04AD90. 
Farmakoterapijska skupina: antiemetici ATCvet kôd: QA04AD90.
Giving your dog a light meal or snack before administering the tablet could help preventing this effect. 
Davanje laganog obroka prije davanja tablete može spriječiti povraćanje.
Prolonged fasting before administration should be avoided. 
Prethodni produženi post se ne preporučuje.
Following repeated oral administration for two consecutive days at a daily dose of 8 mg/kg, accumulation was 218%. 
Praćenjem ponovljene p.o. aplikacije kroz dva uzastopna dana u dozi od 8 mg/kg akumulacija (povećanje koncentracije) je bila 218%.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs and cats with liver disease. 
Maropitant se metabolizira u jetri te se s toga treba oprezno koristiti kod pasa i mačaka s bolestima jetre.
Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range. 
Maropitant pokazuje linearnu kinetiku kada se daje subkutano unutar granica doze od 0,5-2 mg/kg.
To treat or prevent vomiting, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below. 
Za liječenje ili sprječavanje povraćanja, Cerenia tablete treba davati jednom dnevno u dozi od 2 mg maropitanta na kilogram tjelesne težine, koristeći broj tableta naveden u ispod priloženoj tabeli.
One ml of solution contains: 
KVALITATIVNI I KVANTITATIVNI SASTAV Jedna ml otopine sadržava:
However, Cerenia tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of efficacy. 
Tablete Cerenie ne smiju se davati umotane u hranu jer mogu usporiti otapanje tablete i posljedično odgoditi efikasnost.
• For the prevention of nausea induced by chemotherapy. 
• Za sprječavanje mučnine izazvane kemoterapijom.
Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. 
Cerenia otopina za injekciju daje se subkutano, jednom dnevno u dozi od 1 mg/kg tjelesne težine (1 ml/10 kg tjelesne težine) do maksimalno 5 uzastopnih dana.
The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg. 
Volumen distribucije u stabilnom stanju-(Vss) bio je 9,3 l/kg, a sustavni klirens 1,5 l/h/kg.
Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg. 
Klinički znakovi koji uključuju povraćanje kod prve primjene, pojačano slinjenje i mekani feces primijećeni su kada se proizvod daje u dozi većoj od 20 mg/kg.
A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity. 
Niz in vitro testova je pokazao da se maropitant selektivno veže za NK1 receptore funkcionalnim antagonizmom aktivnosti
Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs. 
Maropitant se dobro veže na proteine plazme te može stvarati interakcije s drugim proizvodima koji imaju istu karakteristiku.
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours. 
Najviše koncentracije praćene su smanjenjem sustavne izloženosti s vidljivim vremenom polueliminacije (t1/2) od 8,84 sata.
Metacresol (as preservative) 
Pomoćne tvari: Metakrezola (kao konzervans)
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours. 
Najviše koncentracije praćene su smanjenjem sustavne izloženosti s vidljivim vremenom polueliminacije (t1/2) od 16,8 sati.
Pain at injection site may occur when injected subcutaneously. 
Prilikom subkutane primjene može se pojaviti bolnost na mjestu injiciranja.
For prevention of vomiting induced by motion sickness, (only for dogs 16 weeks of age or older) 
Za sprječavanje povraćanja uzrokovanog bolešću putovanja, (samo za pse starije od 16 tjedana)
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t0.5) of 4.03 hours. 
Najviše koncentracije praćene su smanjenjem sustavne izloženosti s vidljivim vremenom polueliminacije (t1/2) od 4,03 sata.
Cerenia can be used to treat or prevent vomiting either as tablets or as solution for injection administered once daily. 
Cerenia se može davati za liječenje ili sprječavanje povraćanja u obliku tableta ili otopine za injekcije jednom dnevno.
Renal and faecal clearances are minor routes of elimination for maropitant, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine or faeces as maropitant. 
Izlučivanje putem bubrega i fecesa je manje značajan put eliminacije maropitanta, manje od 1% od subkutane doze 1mg/kg eliminira se kao maropitant u urinu ili fecesu.
For motion sickness a light meal or snack before dosing is recommended, prolonged fasting before administration should be avoided. 
Za sprječavanje bolesti putovanja preporučuje se dati lagani obrok prije davanja lijeka, prethodni produženi post se ne preporučuje.
Dogs and cats. 
CILJNE VRSTE ŽIVOTINJA Psi i mačke.
Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance. 
Povećanje QT intervala kod pretrage EKG-om od otprilike 10% zabilježena je u studiji napravljenoj na zdravim psima pasmine bigl, koji su primili dozu od 8 mg/kg p.o.
• For the prevention of vomiting except that induced by motion sickness. 
• Za sprječavanje povraćanja osim onog uzrokovanog bolešću putovanja.
Dogs and cats 
CILJNE VRSTE ŽIVOTINJA Psi i mačke
FAREVA AMBOISE Zone Industrielle, 29 route des Industries 37530 Pocé-sur-Cisse FRANCE 
FAREVA AMBOISE Zone Industrielle, 29 route des Industries
Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%. 
Praćenjem ponovljene subkutane aplikacije jedne dnevne doze od 1 mg/kg kroz pet uzastopnih dana akumulacija (povećanje koncentracije) je bila 146%.
Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease. 
Maropitant se metabolizira u jetri te se s toga treba oprezno koristiti kod pasa s bolestima jetre.
For the prevention of nausea induced by chemotherapy and treatment and prevention of vomiting (except motion sickness), (only for dogs 8 weeks of age or older). 
Sprječavanje mučnine izazvane kemoterapijom, liječenje i sprječavanje povraćanja (osim bolesti putovanja), (samo za pse starije od 8 tjedana).
METHOD AND ROUTE(S) OF ADMINISTRATION 
NAČIN I PUT(EVI) PRIMJENE s.c., i.v.